A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
You are being asked to take part in this study because you have acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and the standard drugs to treat the disease are no longer effective, treatment was not effective for your type of disease, or the standard treatments are not suitable for you. The goal of this clinical research study is to learn if an investigational drug SY-1425 (sometimes known as tamibarotene), when given alone or in combination with azacitidine (Vidaza) or daratumumab (Darzalex), can help to control AML or MDS in patients who have or do not have certain biomarkers. Biomarkers are found in the blood/tissue and may be related to your reaction to SY-1425. Researchers want to learn about the biomarkers being studied and if SY-1425 responds at all, or any better for patients who have the biomarkers, or do not have them. The safety of this drug will also be studied.
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: Tamibarotene
Treatment Location: Both at MDACC & and Other Sites
Sponsor: Syros Pharmaceuticals, Inc.
IRB Review and Approval Date: 11/28/2016
Recruitment Status: Open
Projected Accrual: 137
Information and next steps
Malignant neoplasms stated as primary lymphoid haematopoietic
For general questions about clinical trials: